Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling

March 16, 2021

Heidi J. Einolf

Heidi J. Einolf is director, modeling and simulation, pharmacokinetic sciences, Novartis.

, Stephen D. Hall

Stephen D. Hall

Stephen D. Hall is senior research fellow, drug disposition, Eli Lilly and Co.

, Tracy Williams

Tracy Williams

Tracy Williams is senior director ADME/Toxicology/PKPD, Eli Lilly and Co.

, Aarti Patel

Aarti Patel

Aarti Patel is director, DMPK modeling, GlaxoSmithKline.

, Christopher Gibson

Christopher Gibson

Christopher Gibson is distinguished scientist, Merck.

, Nancy G.B. Agrawal

Nancy G.B. Agrawal

Nancy G.B. Agrawal is vice-president, pharmacokinetics, pharmacodynamics, and drug metabolism, Merck.

, Jens Sydor

Jens Sydor

Jens Sydor is vice-president, DMPK, GlaxoSmithKline.

BioPharm International, BioPharm International-03-15-2021, Volume 2021 eBook, Issue 1

Pages: 27–30

Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.

Predictive sciences—built on improved computational capabilities and a deeper understanding of human physiology—are allowing researchers to perform human studies prior to, and sometimes in place of, human clinical trials in order to predict drug outcomes. Representatives of the Translational & ADME Sciences Leadership Group (TALG) in the IQ Consortium review the basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process.

Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook
March 2021
Pages: 27–30

Citation

When referring to this article, please cite it as H. Einolf, et al., " Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling," BioPharm International Regulatory Sourcebook eBook (March 2021).